44 results on '"Cowen, Philip J."'
Search Results
2. Statins in depression: a repurposed medical treatment can provide novel insights in mental health.
- Author
-
De Giorgi, Riccardo, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
STATINS (Cardiovascular agents) , *PSYCHIATRY , *MENTAL depression , *DIFFUSION of innovations , *PHARMACODYNAMICS - Abstract
Depression has a large burden, but the development of new drugs for its treatment has proved difficult. Progresses in neuroscience have highlighted several physiopathological pathways, notably inflammatory and metabolic ones, likely involved in the genesis of depressive symptoms. A novel strategy proposes to repurpose established medical treatments of known safety and to investigate their potential antidepressant activity. Among numerous candidates, growing evidence suggests that statins may have a positive role in the treatment of depressive disorders, although some have raised concerns about possible depressogenic effects of these widely prescribed medications. This narrative review summarises relevant findings from translational studies implicating many interconnected neurobiological and neuropsychological, cardiovascular, endocrine-metabolic, and immunological mechanisms by which statins could influence mood. Also, the most recent clinical investigations on the effects of statins in depression are presented. Overall, the use of statins for the treatment of depressive symptoms cannot be recommended based on the available literature, though this might change as several larger, methodologically robust studies are being conducted. Nevertheless, statins can already be acknowledged as a driver of innovation in mental health, as they provide a novel perspective to the physical health of people with depression and for the development of more precise antidepressant treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Are neurotransmitters passé? A view from the foothills in response to Rose.
- Author
-
Jauhar, Sameer and Cowen, Philip J.
- Subjects
- *
DRUG therapy for psychoses , *NEUROSCIENCES , *NEUROTRANSMITTERS , *MENTAL depression , *ANTIPSYCHOTIC agents - Published
- 2023
- Full Text
- View/download PDF
4. The Potential Use of Ebselen in Treatment-Resistant Depression.
- Author
-
Ramli, Fitri Fareez, Cowen, Philip J., and Godlewska, Beata R.
- Subjects
- *
ENZYME inhibitors , *PHOSPHATASE inhibitors , *SARS-CoV-2 , *SEROTONIN receptors , *EBSELEN , *NUCLEAR magnetic resonance spectroscopy - Abstract
Ebselen is an organoselenium compound developed as an antioxidant and subsequently shown to be a glutathione peroxidase (GPx) mimetic. Ebselen shows some efficacy in post-stroke neuroprotection and is currently in trial for the treatment and prevention of hearing loss, Meniere's Disease and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In vitro screening studies show that ebselen is also an effective inhibitor of the enzyme inositol monophosphatase (IMPase), which is a key target of the mood-stabilising drug lithium. Further, in animal experimental studies, ebselen produces effects on the serotonin system very similar to those of lithium and also decreases behavioural impulsivity. The antidepressant effects of lithium in treatment-resistant depression (TRD) have been attributed to its ability to facilitate presynaptic serotonin activity; this suggests that ebselen might also have a therapeutic role in this condition. Human studies utilising magnetic resonance spectroscopy support the notion that ebselen, at therapeutic doses, inhibits IMPase in the human brain. Moreover, neuropsychological studies support an antidepressant profile for ebselen based on positive effects on emotional processing and reward seeking. Ebselen also lowers a human laboratory measure of impulsivity, a property that has been associated with lithium's anti-suicidal effects in patients with mood disorders. Current clinical studies are directed towards assessment of the neuropsychological effects of ebselen in TRD patients. It will also be important to ascertain whether ebselen is able to lower impulsivity and suicidal behaviour in clinical populations. The objective of this review is to summarise the developmental history, pre-clinical and clinical psychopharmacological properties of ebselen in psychiatric disorders and its potential application as a treatment for TRD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Subchronic treatment with St John's wort produces a positive shift in emotional processing in healthy volunteers.
- Author
-
Warren, Matthew B., Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
ANTIDEPRESSANTS , *MENTAL depression , *HYPERICUM , *CLINICAL trials , *SHORT-term memory , *COGNITION , *EMOTIONS , *HYPERICUM perforatum , *PLANT extracts , *BLIND experiment , *PHARMACODYNAMICS - Abstract
Background: The neurocognitive model of antidepressant treatment in depression states that antidepressants work by producing relatively immediate positive shifts in emotional processing, which translate into clinical improvement with time. St John's Wort has shown antidepressant potential in randomised controlled trials; however, its pharmacological actions are broad and it is unknown whether treatment also produces changes in emotional processing.Aims: We investigated whether short-term treatment with St John's wort has similar effects on emotional processing to those reported with other antidepressants such as selective serotonergic reuptake inhibitors.Methods: Forty-eight healthy participants were given St John's wort or placebo treatment for seven days. On day 7 they completed a battery of tasks to measure emotional processing and other elements of cognition.Results: St John's wort treatment produced similar changes to other antidepressants, for example reducing recognition of disgusted faces and attention to fearful faces, while increasing memory for positive words. We failed to find evidence for an effect of St John's wort on other aspects of cognition including working memory.Conclusions: These findings lend support to the theory that the production of early positive biases in emotional processing may be a common feature of all clinically effective antidepressants with diverse pharmacological mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study.
- Author
-
De Giorgi, Riccardo, De Crescenzo, Franco, Cowen, Philip J., Harmer, Catherine J., and Cipriani, Andrea
- Subjects
- *
MENTAL depression , *STATINS (Cardiovascular agents) , *ANTIDEPRESSANTS , *PRIMARY care , *PATIENT compliance , *BRIEF psychotherapy - Abstract
Background: Antidepressants are licensed for use in depressive disorders, but non-response and poor adherence to treatment affect a considerable number of patients. Pre-clinical and clinical evidence suggest that statins can augment the effects of antidepressants. However, the acceptability and tolerability of combining statins with antidepressants are unclear, and their add-on efficacy has only been shown in small, short-term clinical trials. Observational data can provide complementary information about treatment effects on larger samples over longer follow-ups. In this study, we therefore assessed the real-world acceptability, tolerability, and efficacy of concomitant antidepressant and statin treatment in depression. Methods: We conducted a population-based cohort study investigating QResearch primary care research database, which comprises the anonymised electronic healthcare records of 35 + million patients over 1574 English general practices. Patients aged 18–100 years, registered between January 1998 and August 2020, diagnosed with a new episode of depression, and commencing an antidepressant were included. Using a between-subject design, we identified two study groups: antidepressant + statin versus antidepressant-only prescriptions. Outcomes of interest included the following: antidepressant treatment discontinuations due to any cause (acceptability) and due to any adverse event (tolerability) and effects on depressive symptoms (efficacy) measured as response, remission, and change in depression score on the Patient Health Questionnaire-9. All outcomes were assessed at 2, 6, and 12 months using multivariable regression analyses, adjusted for relevant confounders, to calculate adjusted odds ratios (aORs) or mean differences (aMDs) with 99% confidence intervals (99% CIs). Results: Compared to antidepressant-only (N 626,335), antidepressant + statin (N 46,482) was associated with higher antidepressant treatment acceptability (aOR2months 0.88, 99% CI 0.85 to 0.91; aOR6months 0.81, 99% CI 0.79 to 0.84; aOR12months 0.78, 99% CI 0.75 to 0.81) and tolerability (aOR2months 0.92, 99% CI 0.87 to 0.98; aOR6months 0.94, 99% CI 0.89 to 0.99, though not long term aOR12 months 1.02, 99% CI 0.97 to 1.06). Efficacy did not differ between groups (range aOR2-12 months 1.00 and 1.02 for response and remission, range aOR2-12 months − 0.01 and − 0.02 for change in depression score). Conclusions: On real-world data, there is a positive correlation between antidepressant treatment adherence and statin use, partly explained by fewer dropouts due to adverse events. The main limitation of our study is its observational design, which restricts the potential to make causal inferences. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Neuroendocrine and Neurochemical Processes in Depression.
- Author
-
Cowen, Philip J
- Subjects
- *
AMINO acid neurotransmitters , *KETAMINE abuse , *HYPOTHALAMIC-pituitary-adrenal axis , *MENTAL depression , *DEPRESSED persons , *METHYL aspartate receptors - Abstract
Neuroendocrine and neurochemical theories of depression continued to be of importance in understanding pathophysiology and suggesting new kinds of pharmacological intervention. Monoamine theories still dominate the neurochemistry of depression and results from monoamine depletion studies suggest that in certain circumstances lowered activity of serotonin and noradrenaline pathways can indeed lead to clinical depressive symptomatology. More recent developments have implicated changes in the amino acid neurotransmitters, GABA and glutamate, in depressed patients; the ability of the NMDA receptor antagonist, ketamine, rapidly to relieve depressive symptomatology has been a spur to much basic research on the cellular mechanism of glutamatergic antidepressant action. The link between inflammation and depression has led to new kinds of immunological investigations in depressed patients and the possibility of targeted anti-inflammatory treatments. Finally HPA axis abnormalities remain a focus of interest, particularly from the point of view of the many medical co-morbidities which frequently complicate chronic depressive disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. New approaches to treating resistant depression.
- Author
-
Cowen, Philip J. and Anderson, Ian M.
- Subjects
- *
MENTAL depression , *THERAPEUTICS , *PSYCHIATRY , *DRUG development , *ANTIPSYCHOTIC agents , *SEROTONIN uptake inhibitors , *EXCITATORY amino acid agents - Abstract
Persistent major depression that does not respond to adequate first- or second-line treatment is a common problem in psychiatry. This article updates evidence on recommended treatment strategies and reviews the prospects of more experimental approaches. The main pharmacological development in recent years has been the demonstration that several atypical antipsychotic drugs are effective adjunctive agents in improving symptoms in depression unresponsive to selective serotonin reuptake inhibitors, although their adverse effect burden is high. There is optimism about novel pharmacological strategies based on glutamatergic and anti-inflammatory mechanisms. It is important to combine drug and psychological treatments whenever possible. With persistent therapeutic engagement, the majority of patients remit eventually, but subsequent relapse remains a problem. Clinicians should pursue an active and collaborative treatment plan that makes use of all effective therapeutic modalities and continues into the relapse-prevention phase. LEARNING OBJECTIVES • Be aware of the concept of treatment-resistant depression as a staged condition and of the limitations of this concept • Update knowledge of the efficacy of recommended treatments for resistant depression, including new pharmacological and brain stimulation approaches • Be aware of the need for persistent therapeutic engagement and time-limited treatment trials to achieve remission and prevent relapse DECLARATION OF INTEREST P.J.C. has been a member of a Lundbeck advisory board. I.M.A. has been a member of advisory boards to Lundbeck, Servier and Alkermes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression.
- Author
-
Smith, Alexander L. W., Harmer, Catherine J., Cowen, Philip J., and Murphy, Susannah E.
- Subjects
- *
ANTIDEPRESSANTS , *SEROTONIN uptake inhibitors , *TRANSCRANIAL magnetic stimulation , *SEROTONIN , *MENTAL depression - Abstract
Clinical depression is a common, debilitating and heterogenous disorder. Existing treatments for depression are inadequate for a significant minority of patients and new approaches are urgently needed. A wealth of evidence implicates the serotonin 1A (5-HT1A) receptor in the pathophysiology of depression. Stimulation of the 5-HT1A receptor is an existing therapeutic target for treating depression and anxiety, using drugs such as buspirone and tandospirone. However, activation of 5-HT1A raphe autoreceptors has also been suggested to be responsible for the delay in the therapeutic action of conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs). This narrative review provides a brief overview of the 5-HT1A receptor, the evidence implicating it in depression and in the effects of conventional antidepressant treatment. We highlight that pre- and post-synaptic 5-HT1A receptors may have divergent roles in the pathophysiology and treatment of depression. To date, developing this understanding to progress therapeutic discovery has been limited, partly due to a paucity of specific pharmacological probes suitable for use in humans. The development of 5-HT1A 'biased agonism', using compounds such as NLX-101, offers the opportunity to further elucidate the roles of pre- and post-synaptic 5-HT1A receptors. We describe how experimental medicine approaches can be helpful in profiling the effects of 5-HT1A receptor modulation on the different clinical domains of depression, and outline some potential neurocognitive models that could be used to test the effects of 5-HT1A biased agonists. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Disturbed sex hormone milieu in males and females with major depressive disorder and low-grade inflammation.
- Author
-
Lombardo, Giulia, Mondelli, Valeria, Worrell, Courtney, Sforzini, Luca, Mariani, Nicole, Nikkheslat, Naghmeh, Nettis, Maria A., Kose, Melisa, Zajkowska, Zuzanna, Cattaneo, Annamaria, Pointon, Linda, Turner, Lorinda, Cowen, Philip J., Drevets, Wayne C., Cavanagh, Jonathan, Harrison, Neil A., Bullmore, Edward T., Dazzan, Paola, and Pariante, Carmine M.
- Subjects
- *
SEX hormones , *DEPRESSION in women , *MENTAL depression , *HORMONE therapy , *IMMUNOSUPPRESSION , *GENDER dysphoria - Abstract
Sex hormones have biological effects on inflammation, and these might contribute to the sex-specific features of depression. C-reactive protein (CRP) is the most widely used inflammatory biomarker and consistent evidence shows a significant proportion (20–30 %) of patients with major depressive disorder (MDD) have CRP levels above 3 mg/L, a threshold indicating at least low-grade inflammation. Here, we investigate the interplay between sex hormones and CRP in the cross-sectional, observational Biomarkers in Depression Study. We measured serum high-sensitivity (hs-)CRP, in 64 healthy controls and 178 MDD patients, subdivided into those with hs-CRP below 3 mg/L (low-CRP; 53 males, 72 females) and with hs-CRP above 3 mg/L (high-CRP; 19 males, 34 females). We also measured interleukin-6, testosterone, 17-β-estradiol (E2), progesterone, sex-hormone binding globulin (SHBG), follicle-stimulating and luteinising hormones, and calculated testosterone-to-E2 ratio (T/E2), free androgen and estradiol indexes (FAI, FEI), and testosterone secretion index. In males, high-CRP patients had lower testosterone than controls (p = 0.001), and lower testosterone (p = 0.013), T/E2 (p < 0.001), and higher FEI (p = 0.015) than low-CRP patients. In females, high-CRP patients showed lower SHGB levels than controls (p = 0.033) and low-CRP patients (p = 0.034). The differences in testosterone, T/E2 ratio, and FEI levels in males survived the Benjamini-Hochberg FDR correction. In linear regression analyses, testosterone (β = −1.069 p = 0.033) predicted CRP concentrations (R2 = 0.252 p = 0.002) in male patients, and SHBG predicted CRP levels (β = −0.628 p = 0.009, R2 = 0.172 p = 0.003) in female patients. These findings may guide future research investigating interactions between gonadal and immune systems in depression, and the potential of hormonal therapies in MDD with inflammation. • Males with MDD show decreased levels of testosterone and TSI. • Females with MDD and healthy controls have similar sex hormone levels. • Males with MDD with high-CRP have decreased levels of testosterone. • Females with MDD and high-CRP have decreased levels of SHBG. • In MDD, CRP levels are predicted by testosterone in males and by SHBG in females. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory.
- Author
-
Chen, Runsen, Capitão, Liliana P., Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
DRUG efficacy , *AUTOBIOGRAPHICAL memory , *FACIAL expression , *TASK performance , *RANDOMIZED controlled trials , *PSYCHOLOGICAL tests , *PRE-tests & post-tests , *BLIND experiment , *DESCRIPTIVE statistics , *EMOTIONS , *STATISTICAL sampling , *CONTROL groups , *ANTIBIOTICS , *PHARMACODYNAMICS , *EVALUATION - Abstract
Background: Studies suggest that d-cycloserine (DCS) may have antidepressant potential through its interaction with the glycine site of the N-methyl-D-aspartate receptor; however, clinical evidence of DCS's efficacy as a treatment for depression is limited. Other evidence suggests that DCS affects emotional learning which may also be relevant for the treatment of depression and anxiety. The aim of the present investigation was to assess the effect of DCS on emotional processing in healthy volunteers and to further characterise its effects on emotional and autobiographical memory. Methods: Forty healthy volunteers were randomly allocated to a single dose of 250 mg DCS or placebo in a double-blind design. Three hours later, participants performed an Emotional Test Battery [including Facial Expression Recognition Task (FERT), Emotional Categorisation Task (ECAT), Emotional Recall Task (EREC), Facial Dot-Probe Task (FDOT) and Emotional Recognition Memory Task (EMEM)] and an Autobiographical Memory Test (AMT). Also, participants performed the FERT, EREC and AMT tasks again after 24 h in order to assess longer lasting effects of a single dose of DCS. Results: DCS did not significantly affect the FERT, EMEM and FDOT performance but significantly increased emotional memory and classification for positive words v. negative words. Also, DCS enhanced the retrieval of more specific autobiographical memories, and this effect persisted at 24 h. Conclusions: These findings support the suggestion that low-dose DCS increases specific autobiographical memory retrieval and positive emotional memory. Such effects make it an intriguing agent for further investigation in clinical depression, which is characterised by decreased autobiographical memory specificity and increased negative bias in memory recall. It also underscores the potential role of DCS as an adjunct to cognitive behavioural therapy in depression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Acute neural effects of fluoxetine on emotional regulation in depressed adolescents.
- Author
-
Capitão, Liliana P., Chapman, Robert, Filippini, Nicola, Wright, Lucy, Murphy, Susannah E., James, Anthony, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
ANTIDEPRESSANTS , *FLUOXETINE , *DRUG efficacy , *COGNITION , *MAGNETIC resonance imaging , *COMPARATIVE studies , *RANDOMIZED controlled trials , *MENTAL depression , *VISUAL perception , *RESEARCH funding , *EMOTION regulation , *STATISTICAL sampling , *NEURORADIOLOGY , *PHARMACODYNAMICS , *ADOLESCENCE - Abstract
Background: Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal. Little is known however about how current pharmacotherapies act to modulate the neural mechanisms underlying these key processes. The current study therefore investigated the neural effects of fluoxetine on emotional reactivity and cognitive reappraisal in adolescent depression. Methods: Thirty-one adolescents with MDD were randomised to acute fluoxetine (10 mg) or placebo. Seventeen healthy adolescents were also recruited but did not receive any treatment for ethical reasons. During functional magnetic resonance imaging (fMRI), participants viewed aversive images and were asked to either experience naturally the emotional state elicited ('Maintain') or to reinterpret the content of the pictures to reduce negative affect ('Reappraise'). Significant activations were identified using whole-brain analysis. Results: No significant group differences were seen when comparing Reappraise and Maintain conditions. However, when compared to healthy controls, depressed adolescents on placebo showed reduced visual activation to aversive pictures irrespective of the condition. The depressed adolescent group on fluoxetine showed the opposite pattern, i.e. increased visuo-cerebellar activity in response to aversive pictures, when compared to depressed adolescents on placebo. Conclusions: These data suggest that depression in adolescence may be associated with reduced visual processing of aversive imagery and that fluoxetine may act to reduce avoidance of such cues. This could reflect a key mechanism whereby depressed adolescents engage with negative cues previously avoided. Future research combining fMRI with eye-tracking is nonetheless needed to further clarify these effects. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge.
- Author
-
Erritzoe, David, Godlewska, Beata R., Rizzo, Gaia, Searle, Graham E., Agnorelli, Claudio, Lewis, Yvonne, Ashok, Abhishekh H., Colasanti, Alessandro, Boura, Iro, Farrell, Chloe, Parfitt, Hollie, Howes, Oliver, Passchier, Jan, Gunn, Roger N., Politis, Marios, Nutt, David J., Cowen, Philip J., Knudsen, Gitte M., and Rabiner, Eugenii A.
- Subjects
- *
POSITRON emission tomography , *RAPHE nuclei , *HAMILTON Depression Inventory , *MENTAL depression , *SEROTONIN , *NEURAL transmission , *SEROTONIN receptors - Abstract
The serotonin hypothesis of depression proposes that diminished serotonergic (5-HT) neurotransmission is causal in the pathophysiology of the disorder. Although the hypothesis is over 50 years old, there is no firm in vivo evidence for diminished 5-HT neurotransmission. We recently demonstrated that the 5-HT 2A receptor agonist positron emission tomography (PET) radioligand [11C]Cimbi-36 is sensitive to increases in extracellular 5-HT induced by an acute d-amphetamine challenge. Here we applied [11C]Cimbi-36 PET to compare brain 5-HT release capacity in patients experiencing a major depressive episode (MDE) to that of healthy control subjects (HCs) without depression. Seventeen antidepressant-free patients with MDE (3 female/14 male, mean age 44 ± 13 years, Hamilton Depression Rating Scale score 21 ± 4 [range 16–30]) and 20 HCs (3 female/17 male, mean age 32 ± 9 years) underwent 90-minute dynamic [11C]Cimbi-36 PET before and 3 hours after a 0.5-mg/kg oral dose of d-amphetamine. Frontal cortex (main region of interest) 5-HT 2A receptor nondisplaceable binding was calculated from kinetic analysis using the multilinear analysis-1 approach with the cerebellum as the reference region. Following d-amphetamine administration, frontal nondisplaceable binding potential (BP ND) was significantly reduced in the HC group (1.04 ± 0.31 vs. 0.87 ± 0.24, p <.001) but not in the MDE group (0.97 ± 0.25 vs. 0.92 ± 0.22, not significant). ΔBP ND of the MDE group was significantly lower than that of the HC group (HC: 15% ± 14% vs. MDE: 6.5% ± 20%, p =.041). This first direct assessment of 5-HT release capacity in people with depression provides clear evidence for dysfunctional serotonergic neurotransmission in depression by demonstrating reduced 5-HT release capacity in patients experiencing an MDE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. A 'fact of the matter' may not exist in scientific narratives.
- Author
-
Cowen, Philip J.
- Published
- 2015
15. A "fact of the matter" may not exist in scientific narratives.
- Author
-
Cowen, Philip J.
- Subjects
- *
ANTIDEPRESSANTS , *SEROTONIN uptake inhibitors , *MENTAL depression , *SEROTONIN - Abstract
A letter to the editor is presented in response to the article "Serotonin and Depression," by D. Healy in the April 21, 2015 issue.
- Published
- 2015
- Full Text
- View/download PDF
16. Can saliva testing replace blood measurements for health monitoring? Insights from a correlation study of salivary and whole blood glutathione in humans.
- Author
-
Ngamchuea, Kamonwad, Batchelor-McAuley, Christopher, Cowen, Philip J., Williams, Clare, Gonçalves, Luís Moreira, and Compton, Richard G.
- Subjects
- *
SALIVA analysis , *HEALTH status indicators , *BLOOD testing , *GLUTATHIONE , *BIOMARKERS , *ENZYMES - Abstract
The feasibility of using saliva samples as diagnostic for health status is assessed. Although blood is regularly used for this purpose, an alternative non-invasive route which yields equivalent clinical information is desirable. The non-invasive saliva testing is validated by comparing its result to that of blood examination. In this investigation, we used glutathione as a paradigmatic example of a biomarker and diagnostic auxiliary. Correlation between the levels of total unbound glutathione, reduced and oxidized, in saliva and whole blood samples from healthy individuals is evaluated. Both salivary and blood glutathione were measured using an enzymatic kinetic assay which was improved to eliminate measurement errors arising from the variation in the enzyme activity from different batches. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Pharmacological interventions for insomnia disorder in adults - Authors' reply.
- Author
-
Cipriani, Andrea, Ostinelli, Edoardo G, and Cowen, Philip J
- Published
- 2022
- Full Text
- View/download PDF
18. Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers.
- Author
-
Bukala, Bernard R., Browning, Michael, Cowen, Philip J., Harmer, Catherine J., and Murphy, Susannah E.
- Subjects
- *
SCOPOLAMINE , *MENTAL depression , *ANTIDEPRESSANTS , *SHORT-term memory , *EMOTIONAL intelligence - Abstract
There has been increasing interest in the antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine. Here we assess, for the first time, whether a transdermal scopolamine patch is sufficient to induce changes in cognition that are consistent with the reported cognitive and antidepressant effects of scopolamine. A scopolamine or placebo patch was administered to healthy volunteers ( n=33) for 17 h in a double-blind, between-subject procedure. There was no clear effect of scopolamine patch on emotional cognition, verbal or working memory, suggesting that the effective dose of scopolamine available through the patch is too low to represent a viable antidepressant mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Effects of various statins on depressive symptoms: is there enough evidence?
- Author
-
De Giorgi, Riccardo, De Crescenzo, Franco, and Cowen, Philip J.
- Subjects
- *
MENTAL depression , *STATINS (Cardiovascular agents) , *RESEARCH , *ANTILIPEMIC agents , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies - Published
- 2021
- Full Text
- View/download PDF
20. The effects of statin monotherapy on depressive symptoms: A systematic review and meta-analysis.
- Author
-
De Giorgi, Riccardo, Waters, Shona, Pesci, Nicola Rizzo, Rosso, Gianluca, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
MENTAL depression , *STATINS (Cardiovascular agents) , *RANDOMIZED controlled trials , *ANTIDEPRESSANTS , *TREATMENT effectiveness , *ANTILIPEMIC agents , *META-analysis , *SYSTEMATIC reviews , *RESEARCH funding - Abstract
Introduction: Statins have been proposed as a strategy for treating depression, but their benefit in the absence of concurrent antidepressant treatment is unclear. This meta-analysis investigated the antidepressant effects of statin monotherapy in the general population.Methods: We conducted a literature search of randomised controlled trials using any statin monotherapy versus any control condition for depressive symptoms. Our primary efficacy outcome was the mean value on any standardised scale for depression at study endpoint. We also measured efficacy at three further timepoints (<6 months, 6-12 months, >12 months), as well as acceptability, tolerability, and safety. Respectively, continuous and dichotomous outcomes were computed using standardised mean difference (SMD) or relative risk (RR) with 95% confidence intervals (CI) using a random-effect model.Results: Pooled analyses did not show that statin monotherapy improves depressive symptoms at endpoint (N = 2712 SMD = -0.18; 95% CI = -0.41 to 0.04), nor at any other specific timepoint. No difference between statins and control was identified for any of the other outcome measures.Discussion: These results differ from those of previous meta-analyses and, compounded by more recently available evidence, suggest that statins may not have intrinsic antidepressant properties, but may be useful for the management of depression in add-on to antidepressants.Limitations: Data from heterogeneous populations and using different statins were pooled, though several sensitivity and subgroup analyses were performed to account for that. PROSPERO registration: CRD42022306653. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=306653. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
21. An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers.
- Author
-
De Giorgi, Riccardo, Quinton, Alice M. G., Waters, Shona, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
REWARD (Psychology) , *VERBAL learning , *VERBAL memory , *EXPERIMENTAL medicine , *SIMVASTATIN , *PSYCHOLOGICAL tests , *ANTIDEPRESSANTS , *DULOXETINE - Abstract
Rationale: Clinical studies suggest that the highly lipophilic, anti-inflammatory molecule, simvastatin, might be an ideal candidate for drug repurposing in the treatment of depression. The neuropsychological effects of simvastatin are not known, but their ascertainment would have significant translational value about simvastatin's influence on mood and cognition. Objectives: We aimed to investigate the effects of simvastatin on a battery of psychological tests and inflammatory markers in healthy volunteers. Methods: Fifty-three healthy subjects were randomly assigned to 7 days of either simvastatin (N = 27) or sucrose-based placebo (N = 26) given in a double-blind fashion. Then, participants were administered questionnaires measuring subjective rates of mood and anxiety, and a battery of tasks assessing emotional processing, reward learning, and verbal memory. Blood samples for C-reactive protein were also collected. Results: Compared to placebo, participants on simvastatin showed a higher number of positively valenced intrusions in the emotional recall task (F1,51 = 4.99, p = 0.03), but also an increase in anxiety scores (F1,51 = 5.37, p = 0.02). An exploratory analysis of the females' subgroup (N = 27) showed lower number of misclassifications as sad facial expression in the simvastatin arm (F1,25 = 6.60, p = 0.02). No further statistically significant changes could be observed on any of the other outcomes measured. Conclusions: We found limited evidence that 7-day simvastatin use in healthy volunteer induces a positive emotional bias while also being associated with an increase in anxiety, potentially reflecting the early effects of antidepressants in clinical practice. Such effect might be more evident in female subjects. Different drug dosages, treatment lengths, and sample selection need consideration in further experimental medicine and clinical studies. Trial registration: Clinicaltrials.gov: NCT04652089. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Frontal Cortex Stimulation Reduces Vigilance to Threat: Implications for the Treatment of Depression and Anxiety.
- Author
-
Ironside, Maria, O’Shea, Jacinta, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
PREFRONTAL cortex , *VIGILANCE (Psychology) , *MENTAL depression , *THERAPEUTICS , *ANXIETY treatment , *AFFECTIVE disorders , *TRANSCRANIAL direct current stimulation - Abstract
Background The difficulty in treating mood disorders has brought about clinical interest in alternative treatments, such as transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC). However, the optimal parameters for stimulation and underlying mechanisms of action are unclear. Psychiatric treatments have acute effects on emotional processing that predict later therapeutic action. Such effects have been proposed as cognitive biomarkers for screening novel treatments for depression and anxiety. Methods This study assessed the effect of tDCS on a battery of emotional processing measures sensitive to antidepressant action. To refine optimal stimulation parameters, DLPFC stimulation using two common electrode montages was compared with sham. Sixty healthy volunteers received 20 minutes of active or sham DLPFC stimulation before completing computerized emotional processing tasks, including a dot-probe measure of vigilance to threat. Results Relative to sham stimulation, participants receiving simultaneous anodal stimulation of left DLPFC and cathodal stimulation of right DLPFC (bipolar-balanced montage) showed reduced vigilance to threatening stimuli. There was no such significant effect when the cathode was placed on the supraorbital ridge (bipolar-unbalanced montage). There were no effects of tDCS on other measures of emotional processing. Conclusions Our findings provide the first experimental evidence that modulating activity in the DLPFC reduces vigilance to threatening stimuli. This significant reduction in fear vigilance is similar to that seen with anxiolytic treatments in the same cognitive paradigm. The finding that DLPFC tDCS acutely alters the processing of threatening information suggests a potential cognitive mechanism that could underwrite treatment effects in clinical populations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Tianeptine in an experimental medicine model of antidepressant action.
- Author
-
Cooper, Charlotte M, Whiting, Daniel A, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
EXPERIMENTAL medicine , *NEUROPSYCHOLOGY , *SEROTONIN , *DRUG efficacy , *THERAPEUTICS ,PHYSIOLOGICAL effects of antidepressants - Abstract
Changes in emotional processing have been shown following acute administration of a range of monoaminergic antidepressants, and may represent an important common neuropsychological mechanism underpinning their therapeutic effects. Tianeptine is an agent that challenges the traditional monoaminergic hypothesis of antidepressant action, though its exact mode of action remains controversial. Healthy volunteers were randomised to receive a single dose of tianeptine (12.5 mg) or placebo, and subsequently completed a battery of tasks measuring emotional processing, including facial expression recognition, emotional memory and attentional vigilance, as well as working and verbal memory. Tianeptine-treated subjects were less accurate at identifying facial expressions, though this was not valence specific. The tianeptine group also showed reduced positive affective memory and reduced attentional vigilance to positive stimuli. There were no effects on emotional categorization or non-emotional cognition. The negative biases in aspects of emotional processing observed following acute tianeptine administration are at variance with the positive biases generally seen after acute administration of conventional antidepressant drugs, despite tianeptine’s putative antidepressant efficacy. This is an intriguing finding in the context of the lack of consensus regarding tianeptine’s mechanism of action; however, it may be consistent with the reported ability of acute tianeptine to increase the re-uptake of serotonin. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. No antidepressant-like acute effects of bright light on emotional information processing in healthy volunteers.
- Author
-
Kaltenboeck, Alexander, Ruzickova, Tereza, Breunhölder, Veronika, Zghoul, Tarek, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
INFORMATION processing , *VOLUNTEERS , *COGNITION , *VOLUNTEER service , *BLIND experiment , *ANIMAL offspring sex ratio , *ANTIDEPRESSANTS , *PHOTOTHERAPY , *BEHAVIORAL assessment , *BEHAVIOR therapy , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *PRE-tests & post-tests , *MENTAL depression , *QUESTIONNAIRES , *EMOTIONS , *STATISTICAL sampling - Abstract
Rationale: Bright light treatment (BLT) is an efficacious antidepressant intervention, but its mechanism of action is not well understood. Antidepressant drugs acutely affect how emotional information is processed, pushing the brain to prioritise positive relative to negative input. Whether BLT could have a similar effect is not known to date. Objective: To test whether BLT acutely influences emotional information processing similar to antidepressant drugs, using an established healthy volunteer assay. Methods: Following a double-blind, parallel-group design, 49 healthy volunteers (18–65 years, 26 females) were randomly allocated to 60-min BLT (≥ 10,000 lux) or sham-placebo treatment early in the morning in autumn/winter. Immediately after treatment, emotional information processing was assessed using the Oxford Emotional Test Battery, a validated set of behavioural tasks tapping into emotional information processing in different cognitive domains. Participants also completed questionnaires before and after treatment to assess changes in subjective state. Results: The BLT group did not show significantly more positively biased emotional information processing compared to the placebo group (p > 0.05 for all measures). After adjustment for pre-treatment scores, there were also no significant post-treatment differences between groups in subjective state (p > 0.05 for all measures). Conclusions: BLT did not show immediate effects on emotional information processing in an established healthy volunteer assay. Thus, BLT might exert its clinical effects through a different (cognitive) mechanism than other antidepressant interventions. Future studies should corroborate this finding including clinical populations and more intensive treatment regimes, and control for potential chronobiological effects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla.
- Author
-
Godlewska, Beata R., Williams, Stephen, Emir, Uzay E., Chen, Chi, Sharpley, Ann L., Goncalves, Ana Jorge, Andersson, Monique I., Clarke, William, Angus, Brian, and Cowen, Philip J.
- Subjects
- *
CHRONIC fatigue syndrome , *NUCLEAR magnetic resonance spectroscopy , *PROTON magnetic resonance spectroscopy , *CINGULATE cortex , *RADIONUCLIDE imaging , *GLUTATHIONE , *LIMBIC system , *NEUROTRANSMITTERS , *COMPARATIVE studies , *CREATINE , *INOSITOL , *ASPARTIC acid ,BRAIN metabolism - Abstract
Rationale: Chronic fatigue syndrome (CFS) is a common and burdensome illness with a poorly understood pathophysiology, though many of the characteristic symptoms are likely to be of brain origin. The use of high-field proton magnetic resonance spectroscopy (MRS) enables the detection of a range of brain neurochemicals relevant to aetiological processes that have been linked to CFS, for example, oxidative stress and mitochondrial dysfunction. Methods: We studied 22 CFS patients and 13 healthy controls who underwent MRS scanning at 7 T with a voxel placed in the anterior cingulate cortex. Neurometabolite concentrations were calculated using the unsuppressed water signal as a reference. Results: Compared to controls, CFS patients had lowered levels of glutathione, total creatine and myo-inositol in anterior cingulate cortex. However, when using N-acetylaspartate as a reference metabolite, only myo-inositol levels continued to be significantly lower in CFS participants. Conclusions: The changes in glutathione and creatine are consistent with the presence of oxidative and energetic stress in CFS patients and are potentially remediable by nutritional intervention. A reduction in myo-inositol would be consistent with glial dysfunction. However, the relationship of the neurochemical abnormalities to the causation of CFS remains to be established, and the current findings require prospective replication in a larger sample. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study.
- Author
-
De Giorgi, Riccardo, Martens, Marieke, Rizzo Pesci, Nicola, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
REWARD (Psychology) , *EXPERIMENTAL medicine , *VERBAL memory , *ATORVASTATIN , *EMOTIONAL conditioning , *NEUROPSYCHOLOGY , *ANTIDEPRESSANTS , *VERBAL learning , *ANTILIPEMIC agents - Abstract
Background: Growing evidence from clinical trials and epidemiological studies suggests that statins can have clinically significant antidepressant effects, potentially related to anti-inflammatory action on several neurobiological structures. However, the underlying neuropsychological mechanisms of these effects remain unexplored. Aims: In this experimental medicine trial, we investigated the 7-day effects of the lipophilic statin, atorvastatin on a battery of neuropsychological tests and inflammation in healthy volunteers. Methods: Fifty healthy volunteers were randomised to either 7 days of atorvastatin 20 mg or placebo in a double-blind design. Participants were assessed with psychological questionnaires and a battery of well-validated behavioural tasks assessing emotional processing, which is sensitive to putative antidepressant effects, reward learning and verbal memory, as well as the inflammatory marker, C-reactive protein. Results: Compared to placebo, 7-day atorvastatin increased the recognition (p = 0.006), discriminability (p = 0.03) and misclassifications (p = 0.04) of fearful facial expression, independently from subjective states of mood and anxiety, and C-reactive protein levels. Otherwise, atorvastatin did not significantly affect any other psychological and behavioural measure, nor peripheral C-reactive protein. Conclusions: Our results reveal for the first time the early influence of atorvastatin on emotional cognition by increasing the processing of anxiety-related stimuli (i.e. increased recognition, discriminability and misclassifications of fearful facial expression) in healthy volunteers, in the absence of more general effects on negative affective bias. Further studies exploring the effects of statins in depressed patients, especially with raised inflammatory markers, may clarify this finding and inform future clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. When Helping Is Risky: The Behavioral and Neurobiological Trade-off of Social and Risk Preferences.
- Author
-
Gross, Jörg, Faber, Nadira S., Kappes, Andreas, Nussberger, Anne-Marie, Cowen, Philip J., Browning, Michael, Kahane, Guy, Savulescu, Julian, Crockett, Molly J., and De Dreu, Carsten K. W.
- Subjects
- *
HELPING behavior in children , *DECISION making , *NEUROTRANSMITTERS , *INDIVIDUALS' preferences , *RISK-taking behavior , *HEALTH behavior - Abstract
Helping other people can entail risks for the helper. For example, when treating infectious patients, medical volunteers risk their own health. In such situations, decisions to help should depend on the individual's valuation of others' well-being (social preferences) and the degree of personal risk the individual finds acceptable (risk preferences). We investigated how these distinct preferences are psychologically and neurobiologically integrated when helping is risky. We used incentivized decision-making tasks (Study 1; N = 292 adults) and manipulated dopamine and norepinephrine levels in the brain by administering methylphenidate, atomoxetine, or a placebo (Study 2; N = 154 adults). We found that social and risk preferences are independent drivers of risky helping. Methylphenidate increased risky helping by selectively altering risk preferences rather than social preferences. Atomoxetine influenced neither risk preferences nor social preferences and did not affect risky helping. This suggests that methylphenidate-altered dopamine concentrations affect helping decisions that entail a risk to the helper. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Translating the promise of 5HT4 receptor agonists for the treatment of depression.
- Author
-
Murphy, Susannah E, de Cates, Angharad N, Gillespie, Amy L, Godlewska, Beata R, Scaife, Jessica C, Wright, Lucy C, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
COGNITION disorders , *ANTIDEPRESSANTS , *ANIMAL experimentation , *SEROTONIN uptake inhibitors , *NEUROPLASTICITY , *CELLULAR signal transduction , *SEROTONIN agonists , *MENTAL depression , *PHARMACODYNAMICS - Abstract
Animal experimental studies suggest that 5-HT4 receptor activation holds promise as a novel target for the treatment of depression and cognitive impairment. 5-HT4 receptors are post-synaptic receptors that are located in striatal and limbic areas known to be involved in cognition and mood. Consistent with this, 5-HT4 receptor agonists produce rapid antidepressant effects in a number of animal models of depression, and pro-cognitive effects in tasks of learning and memory. These effects are accompanied by molecular changes, such as the increased expression of neuroplasticity-related proteins that are typical of clinically useful antidepressant drugs. Intriguingly, these antidepressant-like effects have a fast onset of their action, raising the possibility that 5-HT4 receptor agonists may be a particularly useful augmentation strategy in the early stages of SSRI treatment. Until recently, the translation of these effects to humans has been challenging. Here, we review the evidence from animal studies that the 5-HT4 receptor is a promising target for the treatment of depression and cognitive disorders, and outline a potential pathway for the efficient and cost-effective translation of these effects into humans and, ultimately, to the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
- Author
-
De Giorgi, Riccardo, De Crescenzo, Franco, Rizzo Pesci, Nicola, Martens, Marieke, Howard, Wendy, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
META-analysis , *MENTAL depression , *RANDOMIZED controlled trials , *STATINS (Cardiovascular agents) - Abstract
Background: The burden of depressive disorder is large and new treatment approaches are required. Repurposing widely available drugs such as statins may be a time- and cost-effective solution. Statins have anti-inflammatory and anti-oxidant properties which have been shown to be relevant to the pathophysiology of depression. This study assesses the efficacy, acceptability, tolerability, and safety of statins in major depressive disorder. Methods: Our study is an update and extension of a previous meta-analysis published in 2016 by Salagre et al. We performed a systematic review (PubMed/MEDLINE, Cochrane CENTRAL, ISI Web of Science, CINAHL, and ClinicalTrials.gov until the 1st September 2020) and meta-analysis of randomized controlled trials using any statin against placebo or any other statin in the treatment of major depressive disorder. Our primary efficacy outcome measure was the mean value on any standardized scale for depressive symptoms at 8 weeks of treatment. We also calculated outcomes for efficacy, response, and remission at 2, 4, and 12 weeks, as well as acceptability (dropouts for any cause), tolerability (dropouts due to any adverse event), and safety (any adverse event) outcomes at the studies' endpoints. Furthermore, we conducted an exploratory network meta-analysis for the primary efficacy outcome to identify potential differences between statins. Results: We retrieved five randomized controlled trials meeting our inclusion criteria: four used a statin in addition to an antidepressant and compared it to placebo plus antidepressant, and one compared two statins alone. and one comparing one statin with another. Statins compared to placebo in addition to antidepressants were efficacious at 8 weeks (N = 255, SMD = -0.48, 95% CI = -0.74 to -0. 22) and 12 weeks (N = 134, SMD = -0.47, 95% CI = -0.89 to -0.05, moderate certainty) with no difference for acceptability, tolerability, and safety (low certainty). An exploratory network meta-analysis suggested that the most lipophilic statins, especially simvastatin, could be more efficacious than less lipophilic or hydrophilic molecules. Conclusions: This systematic review suggests the efficacy, acceptability, tolerability, and safety of statins in addition to antidepressants in patients with major depressive disorder. Further clinical trials in different settings are required to test this result. Trial rgistration: PROSPERO registration: CRD42020170938. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. A role for 5-HT4 receptors in human learning and memory.
- Author
-
Murphy, Susannah E., Wright, Lucy C., Browning, Michael, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
ANTIDEPRESSANTS , *CELL receptors , *COGNITION , *EMOTIONS , *MEMORY , *STATISTICAL sampling , *RANDOMIZED controlled trials , *BLIND experiment , *PHARMACODYNAMICS - Abstract
Background: 5-HT4 receptor stimulation has pro-cognitive and antidepressant-like effects in animal experimental studies; however, this pharmacological approach has not yet been tested in humans. Here we used the 5-HT4 receptor partial agonist prucalopride to assess the translatability of these effects and characterise, for the first time, the consequences of 5-HT4 receptor activation on human cognition and emotion. Methods: Forty one healthy volunteers were randomised, double-blind, to a single dose of prucalopride (1 mg) or placebo in a parallel group design. They completed a battery of cognitive tests measuring learning and memory, emotional processing and reward sensitivity. Results: Prucalopride increased recall of words in a verbal learning task, increased the accuracy of recall and recognition of words in an incidental emotional memory task and increased the probability of choosing a symbol associated with a high likelihood of reward or absence of loss in a probabilistic instrumental learning task. Thus acute prucalopride produced pro-cognitive effects in healthy volunteers across three separate tasks. Conclusions: These findings are a translation of the memory enhancing effects of 5-HT4 receptor agonism seen in animal studies, and lend weight to the idea that the 5-HT4 receptor could be an innovative target for the treatment of cognitive deficits associated with depression and other neuropsychiatric disorders. Contrary to the effects reported in animal models, prucalopride did not reveal an antidepressant profile in human measures of emotional processing. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
- Author
-
Sharpley, Ann L, Williams, Clare, Holder, Adele A, Godlewska, Beata R, Singh, Nisha, Shanyinde, Milensu, MacDonald, Orla, and Cowen, Philip J
- Subjects
- *
MANIA , *CLINICAL trials , *BIPOLAR disorder , *LITHIUM carbonate , *PLACEBOS , *EBSELEN - Abstract
Rationale: Lithium is an effective prophylactic and anti-manic treatment in bipolar disorder; however, its use is declining through perceived poor tolerance and toxicity. Lithium inhibits inositol monophosphatase (IMPase), a probable key therapeutic mechanism. The anti-inflammatory drug, ebselen, also inhibits IMPase and appears well-tolerated and safe. Objectives: To assess the efficacy of adjunctive ebselen in mania using the Young Mania Rating Scale (YMRS) (primary outcome) and the Altman Self-Rating Mania (ASRM) Scale and Clinical Global Impression-Severity Scale (CGI-S) among the secondary outcomes. Methods: Randomised, double-blind, placebo-controlled, parallel-group trial conducted between October 2017 and June 2019, at Oxford Health NHS Foundation Trust. Pharmacy-controlled randomisation was computer-generated, with full allocation concealment. In/outpatients (n = 68) aged 18–70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35). Participants received usual clinical care and psychotropic medication. Results: Ebselen was numerically, but not statistically, superior to placebo in lowering scores on the YMRS (adjusted mean difference and 95% confidence interval, − 1.71 (− 5.34 to 1.91), p = 0.35) and ASRM (− 1.36 (− 3.75 to 1.17), p = 0.29). However, scores on the CGI-S were significantly lower at week 3 in ebselen-treated participants (adjusted mean difference, − 0.58 (− 1.14 to − 0.03), p = 0.04). A post hoc analysis excluding patients taking concomitant valproate treatment magnified the difference between ebselen and placebo on the YMRS. Adverse events were comparable between groups, and mild. Conclusions: Ebselen merits further investigation where concomitant psychotropic medication is better controlled and participants taking valproate are excluded. If effective, ebselen's superior tolerance and safety could make it a useful alternative to lithium. Trial registration: Trial Registry: www.clinicaltrials.gov, Identifier: NCT03013400. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Reply to: No Clear Evidence of Reduced Brain Serotonin Release Capacity in Patients With Depression.
- Author
-
Rabiner, Eugenii A., Agnorelli, Claudio, Howes, Oliver, Nutt, David J., Cowen, Philip J., and Erritzoe, David
- Subjects
- *
MENTAL depression , *SEROTONIN , *RAPHE nuclei - Published
- 2023
- Full Text
- View/download PDF
33. Childhood trauma, HPA axis activity and antidepressant response in patients with depression.
- Author
-
Nikkheslat, Naghmeh, McLaughlin, Anna P., Hastings, Caitlin, Zajkowska, Zuzanna, Nettis, Maria A., Mariani, Nicole, Enache, Daniela, Lombardo, Giulia, Pointon, Linda, Cowen, Philip J., Cavanagh, Jonathan, Harrison, Neil A., Bullmore, Edward T., Pariante, Carmine M., and Mondelli, Valeria
- Subjects
- *
HAMILTON Depression Inventory , *ANTIDEPRESSANTS , *MENTAL depression - Abstract
• The severity of childhood trauma experience contributes to lack of response to antidepressant treatment. • Untreated depressed patients show increased diurnal cortisol levels compared with those on antidepressant medication both treatment responder and non-responder patients. • The severity of childhood trauma contributes to increased HPA axis activity and higher cortisol production specifically in depressed patients who present glucocorticoid resistance. • Glucocorticoid resistance may be a novel target for development of personalised treatment for a subgroup of depressed patients with a history of childhood trauma. Childhood trauma is among the most potent contributing risk factors for depression and is associated with poor treatment response. Hypothalamic-pituitary-adrenal (HPA) axis abnormalities have been linked to both childhood trauma and depression, but the underlying mechanisms are poorly understood. The present study aimed to investigate the link between childhood trauma, HPA axis activity and antidepressant response in patients with depression. As part of the Wellcome Trust NIMA consortium, 163 depressed patients and 55 healthy volunteers were included in this study. Adult patients meeting Structured Clinical Interview for Diagnostic and Statistical Manual Version-5 criteria for major depression were categorised into subgroups of treatment responder (n = 42), treatment non-responder (n = 80) and untreated depressed (n = 41) based on current depressive symptom severity measured by the 17-item Hamilton Rating Scale for Depression and exposure to antidepressant medications established by Antidepressant Treatment Response Questionnaire. Childhood Trauma Questionnaire was obtained. Baseline serum C-reactive protein was measured using turbidimetric detection. Salivary cortisol was analyzed at multiple time points during the day using the ELISA technique. Glucocorticoid resistance was defined as the coexistence of hypercortisolemia and inflammation. Our results show that treatment non-responder patients had higher exposure to childhood trauma than responders. No specific HPA axis abnormalities were found in treatment non-responder depressed patients. Untreated depressed showed increased diurnal cortisol levels compared with patients on antidepressant medication, and higher prevalence of glucocorticoid resistance than medicated patients and controls. The severity of childhood trauma was associated with increased diurnal cortisol levels only in individuals with glucocorticoid resistance. Therefore, our findings suggest that the severity of childhood trauma experience contributes to a lack of response to antidepressant treatment. The effects of childhood trauma on increased cortisol levels are specifically evident in patients with glucocorticoid resistance and suggest glucocorticoid resistance as a target for the development of personalized treatment for a subgroup of depressed patients with a history of childhood trauma rather than for all patients with resistance to antidepressant treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Antidepressants, withdrawal, and addiction; where are we now?
- Author
-
Jauhar, Sameer, Hayes, Joseph, Goodwin, Guy M, Cowen, Philip J, Baldwin, David S, and Nutt, David J
- Subjects
- *
SEROTONIN uptake inhibitors , *ANTIDEPRESSANTS , *ADDICTIONS , *KNOWLEDGE gap theory , *DEBATE , *COMPARATIVE studies , *COMPULSIVE behavior , *DRUG withdrawal symptoms , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research - Abstract
Controversy continues with regard to antidepressants and withdrawal. Recent debates have focused on the prevalence and length of withdrawal, and some continue to state that withdrawal from these compounds constitutes 'addiction'. In this editorial we examine the evidence underlying these recent debates. We acknowledge gaps in knowledge, and make suggestions for how the field can progress. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Changes in brain Glx in depressed bipolar patients treated with lamotrigine: A proton MRS study.
- Author
-
Godlewska, Beata R., Emir, Uzay E., Masaki, Charles, Bargiotas, Theodoras, and Cowen, Philip J
- Subjects
- *
HYPOMANIA , *PROTON magnetic resonance spectroscopy , *BIPOLAR disorder , *LAMOTRIGINE , *GLUTAMIC acid , *PROTON magnetic resonance , *ANTIPSYCHOTIC agents , *GLUTAMIC acid metabolism , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *EVALUATION research , *TREATMENT effectiveness ,BRAIN metabolism - Abstract
Background: Lamotrigine is a useful treatment in bipolar depression but requires several weeks of dose titration before its clinical effects can be assessed. Animal experimental studies suggest that lamotrigine lowers glutamate release. The aim of the current study was to assess the effect of lamotrigine on brain glutamate in depressed bipolar patients and to determine whether baseline glutamate could be used to predict clinical response.Methods: We studied 21 bipolar patients who received lamotrigine treatment for a current episode of depression. Before starting lamotrigine and after 10-12 weeks treatment, patients underwent proton magnetic resonance spectroscopy (MRS) scanning at 3 Tesla where levels of glutamate (measured as Glx) were determined in anterior cingulate cortex (ACC).Results: Overall, lamotrigine treatment had no significant effect on Glx levels in ACC. However, in patients who responded clinically to lamotrigine treatment Glx concentrations were significantly increased. Baseline levels of Glx did not predict response to lamotrigine.Limitations: The main limitation of the study was the modest sample size. Most patients were medicated which may have modified the effect of lamotrigine on glutamate activity. MRS at 3T cannot give a reliable estimate of glutamate separate from its main metabolite, glutamine, and thus changes in Glx may not give a precise estimate of effects of lamotrigine on glutamate itself.Conclusion: Lamotrigine does not appear to have a direct effect on glutamate levels in ACC in bipolar patients. However, therapeutic improvement during lamotrigine was associated with increased Glx, suggesting that alterations in glutamatergic activity might be related to recovery from bipolar depression. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Salivary glutathione in bipolar disorder: A pilot study.
- Author
-
Ngamchuea, Kamonwad, Batchelor-McAuley, Christopher, Williams, Clare, Godlewska, Beata R., Sharpley, Ann L., Cowen, Philip J., and Compton, Richard G.
- Subjects
- *
BIPOLAR disorder , *GLUTATHIONE , *SALIVA analysis , *ANTIOXIDANTS , *PATHOLOGICAL physiology , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SALIVA , *PILOT projects , *EVALUATION research , *CASE-control method - Abstract
Background: Glutathione (GSH) is an important cellular antioxidant and its levels are decreased in some studies of bipolar patients. Saliva provides a simple and feasible means of measuring GSH but has not yet been applied to the study of bipolar disorder. The purpose of the study was to compare salivary levels of GSH and oxidized glutathione (GSSG) in bipolar patients and healthy controls.Methods: Saliva was sampled from 22 medicated, euthymic patients with bipolar disorder and 20 healthy controls. GSH and GSSG were measured using an enzyme kinetic essay.Results: GSH and GSSG were significantly higher in saliva from bipolar patients relative to controls. The ratio of GSH:GSSG was unchanged. There was no correlation between the measured clinical characteristics of the patients and GSH levels.Limitations: The main limitation of the study was the small sample size. Patients were medicated which may have influenced saliva production and hence GSH levels. In addition, salivary GSH may not reflect GSH status in tissues more directly involved in the pathophysiology of bipolar disorder.Conclusion: Salivary GSH can be readily measured in bipolar patients. Relative to controls, salivary levels of GSH and GSSG were increased in bipolar patients but their ratio was unchanged. The origin and significance of these change requires further study. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
37. The putative lithium-mimetic ebselen reduces impulsivity in rodent models.
- Author
-
Barkus, Chris, Ferland, Jacqueline-Marie N., Adams, Wendy K., Churchill, Grant C., Cowen, Philip J., Bannerman, David M., Rogers, Robert D., Winstanley, Catharine A., and Sharp, Trevor
- Subjects
- *
IMPULSE control disorders , *BIPOLAR disorder , *AFFECTIVE disorders , *MENTAL illness , *PSYCHOLOGY , *NEUROPROTECTIVE agents - Abstract
Background: Deficits in impulse control feature in many psychiatric conditions including bipolar disorder, suicidality and addictions. Lithium lowers impulsivity in clinical populations and decreases pathological gambling in experimental medicine studies, but suffers from adverse effects, poor compliance and a low therapeutic index.Aims: Recently we identified that the neuroprotective agent ebselen, which is reportedly safe in humans, inhibited inositol monophosphatase (IMPase), a candidate lithium mechanism. Ebselen also reduced 5-HT receptor (5-HT2A) function which predicts impulsivity lowering properties. Here we investigated the effect of ebselen in rat models of impulsive behaviour.Methods: Ebselen was tested in two models of impulsivity with human analogues: the five-choice serial reaction time task (5-CSRTT) and rodent gambling task (rGT). The main outcome measures were premature responses (5-CSRTT and rGT) and choice behaviour (rGT), which model motor impulsivity and choice impulsivity, respectively.Results: At doses that decreased 5-HT2A receptor function (DOI-induced wet dog shakes), ebselen decreased premature responding in the 5-CSRTT both in the absence and presence of cocaine. The 5-HT2A receptor antagonist MDL 100,907 also reduced premature responding in the 5-CSRTT although not in the presence of cocaine. In the rGT ebselen showed a tendency to reduce premature responding but had no effect on choice behaviour.Conclusions: These findings suggest that ebselen preferentially reduces motor impulsivity over choice impulsivity, and that inhibition of 5-HT2A receptor function is a contributing mechanism. Collectively, these data support the repurposing of ebselen as an anti-impulsive treatment and fast-tracking to clinical trials in patient groups characterised by poor impulse control. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
38. Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla.
- Author
-
Godlewska, Beata R., Masaki, Charles, Sharpley, Ann L., Cowen, Philip J., and Emir, Uzay E.
- Subjects
- *
BASAL ganglia , *BRAIN , *MENTAL depression , *MONOSODIUM glutamate , *NEUROPSYCHOLOGY , *NUCLEAR magnetic resonance spectroscopy , *RESEARCH funding , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Background: The possible role of glutamate in the pathophysiology and treatment of depression is of intense current interest. Proton magnetic resonance spectroscopy (MRS) enables the detection of glutamate in the living human brain and meta-analyses of previous MRS studies in depressed patients have suggested that glutamate levels are decreased in anterior brain regions. Nevertheless, at conventional magnetic field strengths [1.5–3 Tesla (T)], it is difficult to separate glutamate from its metabolite and precursor, glutamine, with the two often being measured together as Glx. In contrast, MRS at 7 T allows clear spectral resolution of glutamate and glutamine. Method: We studied 55 un-medicated depressed patients and 50 healthy controls who underwent MRS scanning at 7 T with voxels placed in anterior cingulate cortex, occipital cortex and putamen (PUT). Neurometabolites were calculated using the unsuppressed water signal as a reference. Results: Compared with controls, depressed patients showed no significant difference in glutamate in any of the three voxels studied; however, glutamine concentrations in the patients were elevated by about 12% in the PUT (
p < 0.001). Conclusions: The increase in glutamine in PUT is of interest in view of the postulated role of the basal ganglia in the neuropsychology of depression and is consistent with elevated activity in the descending cortical glutamatergic innervation to the PUT. The basal ganglia have rarely been the subject of MRS investigations in depressed patients and further MRS studies of these structures in depression are warranted. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. Fronto-limbic effective connectivity as possible predictor of antidepressant response to SSRI administration.
- Author
-
Vai, Benedetta, Bulgarelli, Chiara, Godlewska, Beata R., Cowen, Philip J., Benedetti, Francesco, and Harmer, Catherine J.
- Subjects
- *
MENTAL depression , *THERAPEUTICS , *ANTIDEPRESSANTS , *SEROTONIN uptake inhibitors , *FUNCTIONAL magnetic resonance imaging , *BIOMARKERS - Abstract
The timely selection of the optimal treatment for depressed patients is critical to improve remission rates. The detection of pre-treatment variables able to predict differential treatment response may provide novel approaches for treatment selection. Selective serotonin reuptake inhibitors (SSRIs) modulate the fronto-limbic functional response and connectivity, an effect preceding the overt clinical antidepressant effects. Here we investigated whether the cortico-limbic connectivity associated with emotional bias measured before SSRI administration predicts the efficacy of antidepressant treatment in MDD patients. fMRI and Dynamic Causal Modeling (DCM) were combined to study if effective connectivity might differentiate healthy controls (HC) and patients affected by major depression who later responded (RMDD, n =21), or failed to respond (nRMDD, n =12), to 6 weeks of escitalopram administration. Sixteen DCMs exploring connectivity between anterior cingulate cortex (ACC), ventrolateral prefrontal cortex (VLPFC), Amygdala (Amy), and fusiform gyrus (FG) were constructed. Analyses revealed that nRMDD had reduced endogenous connectivity from Amy to VLPFC and to ACC, with an increased connectivity and modulation of the ACC to Amy connectivity when processing of fearful emotional stimuli compared to HC. RMDD and HC did not significantly differ among themselves. Pre-treatment effective connectivity in fronto-limbic circuitry could be an important factor affecting antidepressant response, and highlight the mechanisms which may be involved in recovery from depression. These results suggest that fronto-limbic connectivity might provide a neural biomarker to predict the clinical outcome to SSRIs administration in major depression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study.
- Author
-
Selvaraj, Sudhakar, Mouchlianitis, Elias, Faulkner, Paul, Turkheimer, Federico, Cowen, Philip J., Roiser, Jonathan P., and Howes, Oliver
- Subjects
- *
PRESYNAPTIC receptors , *SEROTONINERGIC mechanisms , *EMOTIONS , *AMYGDALOID body , *SEROTONIN , *BRAIN imaging , *NEURAL circuitry - Abstract
Background The amygdala is a central node in the brain network that processes aversive emotions and is extensively innervated by dorsal raphe nucleus (DRN) serotonin (5-hydroxytryptamine [5-HT]) neurons. Alterations in DRN 5-HT 1A receptor availability cause phenotypes characterized by fearful behavior in preclinical models. However, it is unknown whether 5-HT 1A receptor availability is linked specifically to the processing of aversive emotions in humans or whether it modulates connectivity in brain networks involved in emotion processing. To answer this question, we investigated the relationship between DRN 5-HT 1A receptor availability and amygdala reactivity to aversive emotion and functional connectivity within the amygdala-cortical network. Methods We studied 15 healthy human participants who underwent positron emission tomography scanning with [ 11 C]CUMI-101, a 5-HT 1A partial agonist radioligand, and functional magnetic resonance imaging of brain responses during an incidental emotion processing task including happy, fearful, and neutral faces. Regional estimates of 5-HT 1A receptor binding potential (nondisplaceable) were obtained by calculating total volumes of distribution for presynaptic DRN and amygdala. Connectivity between the amygdala and corticolimbic areas was assessed using psychophysiologic interaction analysis with the amygdala as the seed region. Results Analysis of the fear versus neutral contrast revealed a significant negative correlation between amygdala response and DRN binding potential (nondisplaceable) ( r = −.87, p < .001). Availability of DRN 5-HT 1A receptors positively correlated with amygdala connectivity with middle frontal gyrus, anterior cingulate cortex, bilateral precuneus, and left supramarginal gyrus for fearful (relative to neutral) faces. Conclusions Our data show that DRN 5-HT 1A receptor availability is linked specifically to the processing of aversive emotions in the amygdala and the modulation of amygdala-cortical connectivity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
- Author
-
Pringle, Abbie, Bogdanovskaya, Maria, Waskett, Poppy, Zacharia, Sophie, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
MELATONIN , *EMOTIONS , *ANTIDEPRESSANTS , *SEROTONIN receptors , *DRUG synergism , *PLACEBOS , *SEROTONIN antagonists , *ACETIC acid , *CELL receptors , *CIRCADIAN rhythms , *RESEARCH funding , *HUMAN research subjects , *BLIND experiment , *THERAPEUTICS - Abstract
The antidepressant, agomelatine, has a novel pharmacological profile, with agonist properties at M1 and M2 receptors and antagonist properties at 5HT2C receptors. Whether the antidepressant effects of this treatment are mediated by the drug's effects at the M1 and M2 receptors or the 5HT2C receptor or a synergy between these actions remains unclear. In the present study, a healthy volunteer model of emotional processing, which discriminates between effective and non-effective antidepressant compounds, was used to assess the contribution of melatonin agonism to the efficacy of agomelatine. Fifty-eight healthy volunteers were randomised to receive 7 days of once daily treatment with either 1 mg melatonin, 3 mg melatonin or placebo. Seven days treatment with 3 mg melatonin resulted in earlier bedtimes consistent with a phase advance in circadian rhythm. Some marginal effects of melatonin were observed on emotional processing; however, these were neither consistent with nor comparable to those seen following conventional antidepressant treatment or with agomelatine itself. These data suggest that the antidepressant action of agomelatine cannot be accounted for solely by its action at the M1 and M2 receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. Folic acid supplementation for prevention of mood disorders in young people at familial risk: A randomised, double blind, placebo controlled trial.
- Author
-
Sharpley, Ann L., Hockney, Rena, McPeake, Lily, Geddes, John R., and Cowen, Philip J.
- Subjects
- *
AFFECTIVE disorders , *DIETARY supplements , *FOLIC acid in human nutrition , *RANDOMIZED controlled trials , *PLACEBOS , *PREVENTION - Abstract
Background Clinical mood disorders often become clinically manifest in the later teenage years and early twenties and can be associated with a poor long-term prognosis. The primary prevention of these disorders would therefore have great public health value. Nutritional supplements are a feasible intervention for primary prevention and several epidemiological studies have indicated links between low folate status and depressive symptomatology in the general population. Method A randomised, double blind, parallel group, placebo-controlled trial in which participants, aged 14–24 years, at increased familial risk of mood disorder, were randomised to folic acid (2.5 mg daily) or identical placebo liquid for a maximum of 36 months. Primary outcome data (the onset of a DSM-IV mood disorder) were collected from 112 participants; 56 per group. Results The incidence of mood disorder in the folic acid and placebo groups were 14.3% and 17.9% respectively, a non-significant difference. However, there was post-hoc evidence that folic acid delayed the time to onset of mood disorder in those participants who became unwell. Limitations Small sample size and rate of onset of mood disorders lower than expected. Conclusions Although long term folic acid supplementation was well tolerated, with high levels of adherence, there was no evidence that it reduced the incidence of mood disorder compared to those taking placebo. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Inflammation-related mRNA gene expression absolute levels are associated with treatment-resistant depression in the BIODEP study.
- Author
-
Sforzini, Luca, Cattaneo, Annamaria, Ferrari, Clarissa, Turner, Lorinda, Mariani, Nicole, Enache, Daniela, Hastings, Caitlin, Lombardo, Giulia, McLaughlin, Anna P., Nettis, Maria A., Nikkheslat, Naghmeh, Worrell, Courtney, Zajkowska, Zuzanna, Kose, Melisa, Cattane, Nadia, Lopizzo, Nicola, Mazzelli, Monica, Pointon, Linda, Cowen, Philip J., and Cavanagh, Jonathan
- Subjects
- *
GENE expression , *TRENDS , *MENTAL depression , *MESSENGER RNA - Abstract
Relative mRNA inflammation-related gene expression is increased in treatment-resistant depression (TRD). Here, we aim to investigate the absolute mRNA expression of two pro-inflammatory genes, interleukin (IL)1β and P2X7 receptor (P2RX7). Absolute mRNA quantitation does not require normalization with housekeeping genes but utilizes standard curves to provide a reliable absolute number of molecules. We examined 60 individuals with depression (20 TRD, 20 treatment-responsive, and 20 untreated) and 20 controls from the BIODEP study, using whole-blood mRNA qPCR to measure absolute gene expression. In the entire sample, we confirmed a positive correlation between absolute IL1β and P2RX7 mRNA values and standard values (relative quantitation) (r=0.29, p=0.011 and r=0.22, p=0.05, respectively). In TRD individuals, we demonstrated statistically significant higher IL1β levels (+4.4%; mean±SEM = 7.63±0.07) compared with controls (7.31±0.09) (t =2.70, p=0.010). We also identified a statistical trend towards higher P2RX7 levels in TRD (+5.2%; 3.45±0.07) compared with controls (3.28±0.06) (t =1.79, p=0.08). Absolute gene expression is a valuable instrument to recognize the specific pro-inflammatory gene-expression signature associated with TRD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. An Experimental Medicine Investigation of the Effects of Subacute Pramipexole Treatment on Emotional Information Processing in Healthy Volunteers.
- Author
-
Martens, Marieke Annie Gerdine, Kaltenboeck, Alexander, Halahakoon, Don Chamith, Browning, Michael, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
ANTIDEPRESSANTS , *PRAMIPEXOLE , *EXPERIMENTAL medicine , *FUNCTIONAL magnetic resonance imaging , *DOPAMINE agonists , *INFORMATION processing - Abstract
Treatment with the dopamine D2/D3 receptor agonist pramipexole has demonstrated promising clinical effects in patients with depression. However, the mechanisms through which pramipexole might alleviate depressive symptoms are currently not well understood. Conventional antidepressant drugs are thought to work by biasing the processing of emotional information in favour of positive relative to negative appraisal. In this study, we used an established experimental medicine assay to explore whether pramipexole treatment might have a similar effect. Employing a double-blind, parallel-group design, 40 healthy volunteers (aged 18 to 43 years, 50% female) were randomly allocated to 12 to 15 days of treatment with either pramipexole (at a peak daily dose of 1.0 mg pramipexole salt) or placebo. After treatment was established, emotional information processing was assessed on the neural level by measuring amygdala activity in response to positive and negative facial emotional expressions, using functional magnetic resonance imaging (MRI). In addition, behavioural measures of emotional information processing were collected at baseline and on drug, using an established computerized task battery, tapping into different cognitive domains. As predicted, pramipexole-treated participants, compared to those receiving placebo, showed decreased neural activity in response to negative (fearful) vs. positive (happy) facial expressions in bilateral amygdala. Contrary to our predictions, however, pramipexole treatment had no significant antidepressant-like effect on behavioural measures of emotional processing. This study provides the first experimental evidence that subacute pramipexole treatment in healthy volunteers modifies neural responses to emotional information in a manner that resembles the effects of conventional antidepressant drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.